Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Dose of EN001 in CMT Type 1A
NCT05333406Phase 1Completed
- Sponsor
- ENCell
- Start
- Feb 2022
- Primary completion
- Dec 2022
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of EN001 in Charcot-Marie-Tooth disease type 1A (CMT1A) (2 arms), sponsored by ENCell. Primary endpoints: Number of participants with Adverse Events (AEs)/Serious Adverse Events (SAEs) related to investigational product at 16 weeks, Determination of Dose-limiting toxicity (DLT) levels at 4 weeks and 5 more. Started Feb 2022; status: completed.
02
Drugs
EN001
03
Conditions
Charcot-Marie-Tooth disease type 1A (CMT1A)
Beyond the preview
Go deeper on NCT05333406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05333406.